Analyst Price Target is $6.50
▲ +130.50% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Myomo in the last 3 months. The average price target is $6.50, with a high forecast of $6.50 and a low forecast of $6.50. The average price target represents a 130.50% upside from the last price of $2.82.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Myomo. This Buy consensus rating has held steady for over two years.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, China, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, which includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprise of 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Read More
